Catalyst Pharma's neuromuscular drug succeeds in study

(Reuters) - Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.